In Vivo - Strategic Analysis For Medtech And Pharma Leaders since 1981

Podcasts

Podcast: Noticing Neffy – A ‘Transformative Treatment’ For Type 1 Allergies

Podcast: Noticing Neffy – A ‘Transformative Treatment’ For Type 1 Allergies

 
• By Anabel Costa-Ferreira

Richard Lowenthal, co-founder, and CEO of ARS Pharma, highlights the crucial unmet need for needle-free injections. Challenging issues posed by current epinephrine injectors, In Vivo questions the current and future progression of Neffy.

Podcast: Alpha-Synuclein Testing Comes of Age

 
• By David Wild

In the latest episode of the In Vivo podcast, Russ Lebovitz, the co-founder and scientist behind San Diego's Amprion Diagnostics, discusses the role alpha-synuclein misfolding plays in neurodegenerative diseases and how early alpha-synuclein testing could mitigate the impacts of conditions ranging from Parkinson's disease to Lewy body dementia. 

Podcast: The Future Of R&D Is Self-Driving

 
• By David Wild

In this episode of the In Vivo podcast, visionary University of Toronto researcher Alan Aspuru-Guzik talks about the value of generative AI, automation and quantum computing in drug discovery. 

Podcast: The Colorful Landscape Of Therapeutic Psychedelics

 
• By Anabel Costa-Ferreira

Datamonitor Healthcare analysts and podcast co-hosts Flora Mackay and Emma Wille discuss the complicated development of therapeutic psychedelics. They dwell on FDA involvement and advisory committees, alongside adverse event reporting and ethical concerns.  

Growth

Commercialization 3.0: Achieving New Product Success In Health Care’s New Era

 
• By Harris Kaplan

Despite the importance of developing and commercializing new products to fuel pharma revenue growth, it is estimated that approximately up to 50% of drug launches fail to meet financial expectations. We explore how to maximize product success in pharma's value era.

China Makes Its Presence Felt In Asia 100 Sales

 
• By Ian Haydock

While Japanese firms still dominate the money spinners in Asia, companies from China and, lesser so, India are starting to stand out from the crowd.

A Familiar Leading Pack Conceals Changes For Off-Patent Industry Leaders

 
• By Dave Wallace

Our latest ranking of the world’s leading off-patent companies reflects a fairly stable leading group this year – but this belies the significant evolutions seen for major generics and biosimilars players over the past 12 months.

Innovation

ATMP Manufacturing: Complex Challenges Require Complex Solutions

ATMP Manufacturing: Complex Challenges Require Complex Solutions

 
• By Eliza Slawther

Experts working in the advanced therapy sector tell In Vivo how novel solutions can empower cell and gene therapy manufacturers to reduce costs, improve scalability and optimize their processes – improving the clinical profile and commercial viability of products.

Neoadjuvant Cancer Immunotherapy Set For Takeoff, Fueled By Strong Data

 
• By Emily Hayes

Dreams of a future with early curative treatments drives wave of drug development in pre-surgical and perioperative treatment in many tumor types.

The Practice-Changing Drugs That Will Graduate In 2025

 
• By Daniel Chancellor

A wealth of new therapies are set to successfully graduate from the pipeline in 2025. Within this cohort are a mixture of therapeutic areas, drug classes, first-time approvals, label expansions, and treatments that will meaningfully change how diseases are treated.

Korea Lays Out Roadmap For Use Of AI Across Drug Development

 
• By Jung Won Shin

The five-year roadmap aims to expand support for AI research and development in essential health care and new drug development, as well as advance medical data usage systems and enable its safe use.

Transnational Collaborative Health Tech Assessments Have Much To Offer

 
• By Francesca Bruce

European cross-border HTA collaborations have much to learn from each other to keep drug prices from rising unfairly, say Nordic health technology assessment experts. Talks on HTA collaborations outside Europe are also underway.

Google’s New Drug Discovery And Development LLM

 
• By David Wild

A new large language model by Google Research and DeepMind is the most comprehensive tool yet to potentially expedite drug development and reduce the risk of failure.

Leadership

Execs On The Move: October 2024

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

A Decade On, How Deep Do Regeneron’s Oncology Foundations Go?

 
• By Jo Shorthouse

Regeneron’s clinical and commercial oncology leaders talk to In Vivo about making good on the company’s oncology strategy and pushing the commercial accelerator in a post-Sanofi world.

Winning With Partnerships: How To Turn A Three-Decade-Old Biotech Profitable

 
• By David Wild

Since taking on the CEO role at Theratechnologies in 2020, Paul Lévesque has made it his priority to beef up the company’s commercial portfolio and look for partnerships on potentially high-value programs. Now, the Canadian biotech is turning a profit for the first time in many years.

Market Access

Uncertainty Remains Over The Future Of Regulatory Data Protection In The EU

Uncertainty Remains Over The Future Of Regulatory Data Protection In The EU

 
• By Ian Schofield

As talks continue on the EU pharmaceutical legislative reform proposals, drug firms may have to wait some time before they find out what the future periods of regulatory data protection and orphan market exclusivity will be.

Korea Lays Out Roadmap For Use Of AI Across Drug Development

 
• By Jung Won Shin

The five-year roadmap aims to expand support for AI research and development in essential health care and new drug development, as well as advance medical data usage systems and enable its safe use.

Transnational Collaborative Health Tech Assessments Have Much To Offer

 
• By Francesca Bruce

European cross-border HTA collaborations have much to learn from each other to keep drug prices from rising unfairly, say Nordic health technology assessment experts. Talks on HTA collaborations outside Europe are also underway.

Nordic HTA Body Tells Pharma Users: ‘Feel the Fear And Do It Anyway’

 
• By Francesca Bruce

It is time for companies to take part in cross-country health technology assessments and stop only asking “what’s in it for me?”

Big Pharma Faces A Big Reality Check In Cell And Gene Therapy

 
• By Mandy Jackson

Big pharma executives at ARM’s Cell and Gene Meeting on the Mesa shared some of the practical challenges of bringing one-time treatments to market in hemophilia, cancer and beyond.

New Pharma Research Law Fails To Make Germany More Competitive Says EUCOPE Head

 
• By Francesca Bruce

Germany’s Medical Research Act clears its final legal hurdle after federal council sign off.

Market Intelligence

Uncertainty Remains Over The Future Of Regulatory Data Protection In The EU

 
• By Ian Schofield

As talks continue on the EU pharmaceutical legislative reform proposals, drug firms may have to wait some time before they find out what the future periods of regulatory data protection and orphan market exclusivity will be.

Commercialization 3.0: Achieving New Product Success In Health Care’s New Era

 
• By Harris Kaplan

Despite the importance of developing and commercializing new products to fuel pharma revenue growth, it is estimated that approximately up to 50% of drug launches fail to meet financial expectations. We explore how to maximize product success in pharma's value era.

China Makes Its Presence Felt In Asia 100 Sales

 
• By Ian Haydock

While Japanese firms still dominate the money spinners in Asia, companies from China and, lesser so, India are starting to stand out from the crowd.